GlaxoSmithKline: starts phase III trial for polyps drug.
(CercleFinance.com) - GlaxoSmithKline said on Tuesday that it had started a phase III study with a treatment for patients suffering from severe nasal polyps.
The study will assess the efficacy and safety of subcutaneous mepolizumab compared to placebo, administered every 4 weeks for 52 weeks, on top of standard of care in 400 adult patients.
Nasal polyps is a chronic inflammatory disease of the nasal passage linings or sinuses leading to nasal obstruction, post nasal drip, loss of smell, facial pain, facial pressure and nasal discharge.
The current standard of care is treatment with corticosteroids or surgery.
Mepolizumab has already been approved for severe eosinophilic asthma in the EU and Japan.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The study will assess the efficacy and safety of subcutaneous mepolizumab compared to placebo, administered every 4 weeks for 52 weeks, on top of standard of care in 400 adult patients.
Nasal polyps is a chronic inflammatory disease of the nasal passage linings or sinuses leading to nasal obstruction, post nasal drip, loss of smell, facial pain, facial pressure and nasal discharge.
The current standard of care is treatment with corticosteroids or surgery.
Mepolizumab has already been approved for severe eosinophilic asthma in the EU and Japan.
Copyright (c) 2017 CercleFinance.com. All rights reserved.